title: Relationship between neurologic deficit severity and final functional outcome shifts and strengthens during first hours after onset.
abstract: OBJECTIVE
  Early neurological deficit severity is the most important determinant of final functional outcome in acute ischemic stroke. However, deficit severity frequently changes during the first hours and days postonset.
  
  
  METHODS
  Analysis of control group patients enrolled in the 2 National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials. Neurological deficit severity was measured serially using the National Institutes of Health Stroke Scale (NIHSS) at 1 to 3 hours postonset, 3 to 5 hours, 24 hours, 7 to 10 days, and 90 days. Final global disability outcome was assessed at 90 days using the modified Rankin Scale.
  
  
  RESULTS
  Among the 312 patients, median neurological deficit severity on the NIHSS improved throughout the 90-day observation period, from 15 (interquartile range, 9.5-20) at 1 to 3 hours, to 12 (interquartile range, 6-19) at 24 hours, to 7 (interquartile range, 2-19) at 90 days. Between 1-to-3-hours to 24 hours, more patients spontaneously improved than worsened: 39.1% versus 17.6% (P<0.001). NIHSS scores associated with individual final modified Rankin Scale global disability ranks shifted to lower values over time; eg, patients with a final modified Rankin Scale of 2 had the following median NIHSS scores: 12 at 1 to 3 hours, 10 at 3 to 5 hours, 9 at 24 hours, and 3 at 90 days. Correlation coefficients between NIHSS and the final modified Rankin Scale increased over time, from 0.51 at 1 to 3 hours, to 0.72 at 24 hours, to 0.87 at 90 days.
  
  
  CONCLUSIONS
  During the first 24 hours after onset, spontaneous improvement occurs in 2 of 5 acute ischemic stroke patients. The NIHSS scores associated with individual global disability ranks decrease over time. Neurological deficit severity increasingly predicts final disability outcome, accounting for one quarter of the variance at 1 to 3 hours, one half at 24 hours, and three quarters at 90 days.
authors.affiliation: Stroke Center and Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA. jsaver@ucla.edu
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Saver
authors.forename: Hernan
authors.initials: H
authors.lastname: Altman
mesh_terms: D000208:Acute Disease; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009422:Nervous System Diseases / Q000209:etiology / Q000503:physiopathology*; D012720:Severity of Illness Index; D020521:Stroke / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator